Search company, investor...

About Epsy Health

Epsy Health is a leading digital health platform for the management of epilepsy that empowers patients, caregivers, and healthcare professionals. Epsy provides patients and physicians with actionable insights that can help to accelerate the pathway towards better outcomes.

Headquarters Location

100 Cyberonics Boulevard

Houston, Texas, 77058,

United States


Epsy Health's Product Videos

Epsy Hub General 1 1200 675 CTA.png

Epsy Health's Products & Differentiators

    Epsy App

    For patients and family caregivers, Epsy App is the daily companion to help track the things that matter


Latest Epsy Health News

Outcomes similar with heart donation after circulatory death vs. brain death

Jun 8, 2023

Disclosures: DeVore reports receiving advisory board, consultant, speaking and/or travel fees from Abbott Vascular, Abiomed, American Regent, Amgen, AstraZeneca, Biofourmis, Bodyport, Cardionomic, CareDx, Cytokinetics, InnaMed, LivaNova USA, Medscape, Novartis, Novo Nordisk, Procyrion, Story Health, Vifor and Zoll Services. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Key takeaways: Outcomes were similar for transplants of donor hearts after circulatory death vs. transplants of donor hearts after brain death. There were no differences between the groups in serious adverse events at 30 days. Data show 6-month survival after transplantation with a donor heart reanimated with extracorporeal nonischemic perfusion after circulatory death was similar to 6-month survival after transplantation of a donor heart after brain death. The method, known as donation after circulatory death (DCD), could potentially expand the pool of available donor hearts by a projected 30%, according to Adam D. DeVore, MD, associate professor of medicine at Duke University School of Medicine and member in the Duke Clinical Research Institute. Currently, the need for heart transplants far exceeds the availability of suitable donor allografts; the use of hearts from DCD has been evaluated on the basis of clinical outcomes at single centers in Australia and the United Kingdom. Outcomes were similar for transplants of donor hearts after circulatory death vs. transplants of donor hearts after brain death. Image: Adobe Stock “There are many patients whose families want to be able to donate their hearts, but the patient does not meet the formal criteria for brain death,” DeVore told Healio. “These are still-healthy hearts and families who are still interested in donation for heart transplantation. DCD gives us a means to do that, and the study provides robust, high-quality evidence that it is safe. We see outcomes here that are at least as good as with traditional transplantation.” Adam D. DeVore In a randomized noninferiority trial, DeVore and colleagues analyzed data from 180 adult candidates for heart transplant who were assigned to a heart after the circulatory death of the donor or a heart from a donor after brain death if that heart was available first (circulatory-death group; n = 90) or to only a heart that had been preserved with the use of traditional cold storage after the brain death of the donor (brain-death group; n = 90). “It is important to recognize how rare it is to conduct randomized clinical trials in heart transplant,” DeVore said in an interview. “It was a strategy trial where patients were randomized at the time of listing to either access to DCD donors or the traditional pathway. If a patient participated and they were randomized to the usual care arm, that means they would only be allowed to accept transplants from donors who died from brain death. If randomized to the intervention, they could receive donor hearts from either means, whichever became available faster.” The primary endpoint was risk-adjusted survival at 6 months in the as-treated circulatory-death group compared with the brain-death group. The primary safety endpoint was serious adverse events associated with the heart graft at 30 days after transplantation. The findings were published in The New England Journal of Medicine. Within the cohort, 166 transplant recipients were included in the as-treated primary analysis, including 80 who received a heart from a circulatory-death donor and 86 who received a heart from a brain-death donor. The risk-adjusted 6-month survival in the as-treated population was 94% (95% CI, 88-99) among recipients of a heart from a circulatory-death donor and 90% (95% CI, 84-97) among recipients of a heart from a brain-death donor, for a least-squares mean difference of 3 percentage points, beating the noninferiority margin of 20 percentage points (90% CI, 10 to 3; P < .001 for noninferiority). There were no between-group differences in the mean per-patient number of serious adverse events associated with heart graft at 30 days after transplant. “The data seem to even favor DCD for transplantation; the subsequent follow-up data and our own experience here at Duke is that these recipients do really well,” DeVore said. DeVore said the potential to transplant hearts via DCD could also improve transplant timing, meaning patients in need of a transplant receive a heart earlier in their disease course, which would aid recovery after the transplant. “We talk a lot about innovations in transplantation and some of them are things that require a lot of advancement in science and changes to our existing health structures,” DeVore told Healio. “This involves donor hearts that are already available, today. Now, we are able to use them. It is a really big leap to be able to expand the donor pool that fast, with an already existing donor pool, within the current system.” For more information:

Epsy Health Frequently Asked Questions (FAQ)

  • Where is Epsy Health's headquarters?

    Epsy Health's headquarters is located at 100 Cyberonics Boulevard, Houston.

  • Who are Epsy Health's competitors?

    Competitors of Epsy Health include Nile AI.

  • What products does Epsy Health offer?

    Epsy Health's products include Epsy App and 1 more.


Compare Epsy Health to Competitors

Neuro Event Labs

Neuro Event Labs is a company that focuses on the development of medical technology in the healthcare sector. The company's main product is a smart solution for seizure detection that combines artificial intelligence and human expertise. This solution involves a personal recording unit that captures video and audio data, which is then analyzed by AI algorithms to detect seizure behavior. The results are presented in an interactive report that can be reviewed by a physician. It was founded in 2015 and is based in Tampere, Finland.

Helpilepsy Logo

Helpilepsy is a digital healthcare company focused on improving the management of epilepsy. The company offers a digital platform that includes a mobile app for patients to track seizures, side effects, and medication, and a web dashboard for neurologists to visualize patient data. This platform primarily serves the healthcare industry, specifically neurologists and patients dealing with epilepsy. It was founded in 2017 and is based in Kraainem, Belgium.


Neuroventis is a company that focuses on digital health in neurology. The company offers a digital platform that empowers patients with neurological disorders to actively participate in managing their conditions, and provides healthcare professionals with real-time data to support evidence-based medicine. The platform is used primarily in the healthcare industry. It was founded in 2017 and is based in Overijse, Belgium.


EnlitenAI is a digital health startup focused on the healthcare industry. The company offers a software as a service (SaaS) platform for personalized management of seizures and epilepsy, using wearable technology for continuous monitoring of vitals and other neurological indicators. EnlitenAI primarily serves the healthcare sector, with a specific focus on neurological health management. It was founded in 2020 and is based in San Francisco, California.

Nile AI Logo
Nile AI

Nile is an independent company that seeks to improve care for people living with epilepsy, their caregivers, and healthcare providers. Nile's digital platform consists of a patient app and HCP portal. The patient app is an intuitive, smart tool for patients to feel connected with their care team, learn about their journey, and understand their progress. The HCP portal shows the status of their patients at a glance, virtually informs and supports their patients in between appointments, and allows data-driven decisions on treatment and care.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.